M. Peet

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
M Peet, M. Peet, M. Van Peet, Malcolm Peet
Publication record
140 papers · 6,914 citations · H-index 37

PAPERS

More Harm than Good? A Pilot of a Motivational Interviewing Based Intervention for Increasing Readiness to Improve Nutrition in Young People Experiencing a First Episode of Psychosis
20191 citationsauthor #2
Urine-incontinentie na CVA
20160 citationsauthor #1
Omega-3 Fatty Acids in the Treatment of Psychiatric Disorders
2012167 citationsauthor #1
18 – Fatty acids and schizophrenia
20117 citationsauthor #1
Nurse prescribing in specialist mental health (part 1): the views and experiences of practising and non-practising nurse prescribers and service users.
201136 citationsauthor #3
Nurse prescribing in specialist mental health (part 2): the views and experiences of psychiatrists and health professionals.
201117 citationsauthor #3
Increased breath ethane and pentane concentrations in currently unmedicated patients with schizophrenia
201116 citationsauthor #3
Comparison of Therapeutic Effects of Omega-3 Fatty Acid Eicosapentaenoic Acid and Fluoxetine, Separately and in Combination, in Major Depressive Disorder
2008238 citationsauthor #8
Omega-3 polyunsaturated fatty acids in the treatment of schizophrenia.
200854 citationsauthor #1
Separately and in Combination , in Major Depressive Disorder Comparison of Therapeutic Effects of Omega-3 Fatty Acid Eicosapentaenoic Acid and Fluoxetine ,
20084 citationsauthor #8
0019 NUTRITION AND SCHIZOPHRENIA
20060 citationsauthor #1
Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry.
2006747 citationsauthor #6
Sixty consecutive attenders in remission at a lithium clinic
20060 citationsauthor #1
The metabolic syndrome, omega-3 fatty acids and inflammatory processes in relation to schizophrenia.
200624 citationsauthor #1
QSAR modeling and transmission electron microscopy stereology of altered mitochondrial ultrastructure of white blood cells in patients diagnosed as schizophrenic and treated with antipsychotic drugs.
200536 citationsauthor #2
Diabetes and schizophrenia: interdisciplinary working and lifestyle approaches are key
20050 citationsauthor #1
Nutrition and schizophrenia.
20051 citationsauthor #1
Using an Integrated Care Pathway to Deliver a Nurse-Led Clozapine Clinic
20048 citationsauthor #3
Nutrition and schizophrenia: beyond omega-3 fatty acids.
200459 citationsauthor #1
International variations in the outcome of schizophrenia and the prevalence of depression in relation to national dietary practices: An ecological analysis
2004183 citationsauthor #1
Dietary sugar and polyunsaturated fatty acid consumption as predictors of severity of schizophrenia symptoms.
200452 citationsauthor #2
Pathways to care in first episode psychosis.
200454 citationsauthor #3
Short Communication
20045 citationsauthor #2
International variations in the outcome International variations in the outcome of schizophrenia and the prevalence of depression of schizophrenia and the prevalence of depression in relation to national dietary practices: in relation to national dietary practices:
20040 citationsauthor #1
Diet, diabetes and schizophrenia: Review and hypothesis
2004138 citationsauthor #1
Polyunsaturated fatty acid levels in red cell membranes of unmedicated schizophrenic patients
200451 citationsauthor #1
Developing Integrated Care Pathways in Mental Health: The Critical Success Factors
20036 citationsauthor #2
Nutrition and Schizophrenia: An Epidemiological and Clinical Perspective
200314 citationsauthor #1
Eicosapentaenoic acid in the treatment of schizophrenia and depression: rationale and preliminary double-blind clinical trial results.
2003111 citationsauthor #1
A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs.
2002619 citationsauthor #1
Integrated Care Pathways in Mental Health: The Need for the ‘Human Touch’
20027 citationsauthor #1
A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms.
2002314 citationsauthor #1
Phospholipid metabolism and schizophrenia: new clinical trials
20020 citationsauthor #1
Essential fatty acids: theoretical aspects and treatment implications for schizophrenia and depression
200221 citationsauthor #1
Eicosapentaenoic Acid: A Potential New Treatment for Schizophrenia?
20012 citationsauthor #1
Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia.
2001355 citationsauthor #1
Relationship of symptomatology, gender, and antipsychotic drug treatment with plasma homovanillic acid in schizophrenia.
20012 citationsauthor #4
Double blind pilot study of eicosapentaenoic acid (EPA) as the sole treatment for schizophrenia
200010 citationsauthor #3
Unmedicated schizophrenic patients have a reduced skin flush in response to topical niacin.
200059 citationsauthor #3
ethyleicosapentaenat High-purity and other EPA derivatives for treatment of neurological diseases
20000 citationsauthor #1
Relationship of drug treatment, symptomatology and gender with plasma HVA in schizophrenia
20000 citationsauthor #2
376. Eicosanoid pathways and psychiatric disorders
20002 citationsauthor #6
Etil epa highly purificaco and other epa derivatives for neurological disorders.
20000 citationsauthor #1
A multicentre trial of ethyl eicosapentaenoate in schizophrenia
20007 citationsauthor #1
Retinal function as a marker for cell membrane omega-3 fatty acid depletion in schizophrenia: a pilot study.
199968 citationsauthor #3
Double-blind placebo controlled trial of N-3 polyunsaturated fatty acids as an adjunct to neuroleptics
199823 citationsauthor #1
Glutathione peroxidase (GSHPx) activity in plasma and fibroblasts from schizophrenics and control
19986 citationsauthor #6
Eicosapentaenoic acid (EPA) as an adjunct in the treatment of schizophrenia
199825 citationsauthor #5
Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients.
1998484 citationsauthor #2
Genetic differences in phospholipase A2 in control and schizophrenic population
19982 citationsauthor #6
Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients.
1998612 citationsauthor #1
Sertindole controlled symptoms of schizophrenia without motor side effects
19980 citationsauthor #1
Is the polymorphic (CA)n repeat at the human cPLA2 locus associated with schizophrenia
19970 citationsauthor #4
Infant feeding and tile development of schizophrenia
199712 citationsauthor #1
Cell membrane abnormalities In schizophrenia: Implications for treatment
19970 citationsauthor #1
Plasma TBARS levels in unmedicated chronic schizophrenic patients
19971 citationsauthor #1
Depletion of docosahexanoic acid in erythrocyte membranes of depressive patients
19971 citationsauthor #1
Fatry acid supplementation in schizophrenic patients
19976 citationsauthor #1
Lipids, depression and physical diseases
199722 citationsauthor #1
When fluoxetine fails, what next? A national survey controlling for age
19970 citationsauthor #3
LETTER TO THE EDITOR. Treatment‐Resistant Depression in the Elderly
19960 citationsauthor #2
Omega‐3 fatty acid supplementation in schizophrenic patients
199669 citationsauthor #3
Teaching schizophrenic patients about their depot neuroleptic medication
19960 citationsauthor #1
Reduced susceptibility to oxidative damage of erythrocyte membranes from medicated schizophrenic patients.
199616 citationsauthor #6
Decreased tyrosine transport in fibroblasts from schizophrenics: implications for membrane pathology.
199523 citationsauthor #2
Biological Basis of Substance Abuse. Edited by Stanley G. Korenman and Jack D. Barchas Oxford: Oxford University Press. 1993. 516 pp. £65.00 (hb).
19950 citationsauthor #1
Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients.
1995150 citationsauthor #1
Drug-Induced Mania
199569 citationsauthor #1
Schizophrenic Symptoms and Dietary Intake of N-3 Fatty Acids
199568 citationsauthor #3
Induction of Mania with Selective Serotonin Re-uptake Inhibitors and Tricyclic Antidepressants
1994430 citationsauthor #1
Arachidonic acid: a common link in the biology of schizophrenia?
199460 citationsauthor #1
Tardive dyskinesia, lipid peroxidation and vitamin E
19931 citationsauthor #1
Fundamentals of Psychopharmacology. By B. E. Leonard. Chichester Wiley. 267 pp. £14.95.
19931 citationsauthor #1
Guidelines for treating depressive illness with antidepressants
199376 citationsauthor #12
The prevention of suicide in patients with recurrent mood disorder
19920 citationsauthor #1
Commentary on 'The management of treatment-resistant affective disorder: clinical perspectives'
19920 citationsauthor #1
Neurotransmitters and Drugs. 3rd Edition. By Zygmunt L. Kruk and Christopher J. Pycock. London: Chapman & Hall. £11.95.
19923 citationsauthor #1
The ratio of plasma phenylalanine to other large neutral amino acids is not a risk factor for tardive dyskinesia
19921 citationsauthor #4
Current and Future Trends in Anticonvulsant, Anxiety and Stroke Therapy: Progress in Clinical and Biological Research, Volume 361. Edited by Brian Meldrum and Michael Williams. New York: Wiley-Liss Ltd. 1990. 555 pp. US$142.00.
19920 citationsauthor #1
Lithium Maintenance: 1. A Standard Education Programme for Patients
1991172 citationsauthor #1
Supersensitivity psychosis.
19912 citationsauthor #1
SUPERSENSITIVITY PSYCHOSIS. AUTHOR'S REPLY
19910 citationsauthor #1
Antidepressant drug treatment in relation to the use of ECT
199114 citationsauthor #4
Supersensitivity psychosis [5]
19910 citationsauthor #1
Community Care Works: Learning from the Torbay experience. By Virginia Beardshaw and Edith Morgan. 1990. Pp. 151. £9.50. MIND Mail Order Service, 4th Floor, 24–32 Stephenson Way, London NW1 2HD
19914 citationsauthor #1
Hospitality Management: A Case Study Approach
19910 citationsauthor #2
Lithium Maintenance: 2. Effects of Personality and Attitude on Health Information Acquisition and Compliance
199181 citationsauthor #2
Authors' reply
19910 citationsauthor #2
Hospitality Management: A Case Study Approach - Instructor's Manual
19900 citationsauthor #2
Human Psychopharmacology: Measures and Methods, Volume 2. Edited by I. Hindmarch and P. D. Stonier. Chichester: John Wiley. 1989. 296 pp. £35.50.
19900 citationsauthor #1
Use of Carbamazepine in Psychosis after Neuroleptic Malignant Syndrome
199024 citationsauthor #1
Use of Anticonvulsants in Psychiatry: Recent Advances. Edited by Susan L. McElroy and Harrison G. Pope. New Jersey: Oxford Health Care Inc. 1988. 188 pp. $22.50.
19890 citationsauthor #1
The use of electroconvulsive therapy in elderly depressive patients
19893 citationsauthor #2
A collaborative approach to AIDS education.
19890 citationsauthor #1
Lofepramine in clinical practice.
19883 citationsauthor #1
Vanadium and other trace elements in patients taking lithium.
198816 citationsauthor #2
Depression and Mania: Modern Lithium Therapy. Edited by F. Neil Johnson. Oxford: IRL Press. 1987. 281 pp. £40.00, $75.00.
198810 citationsauthor #1
Increased bromide levels in serum and hair during lithium treatment.
198611 citationsauthor #3
Network Community Mental Health Care in North-West Derbyshire
19866 citationsauthor #1
Propranolol and Atenolol in the Treatment of Anxiety
198617 citationsauthor #1

TIMELINE

1972 140 citations

1973 162 citations

1974 41 citations

1975 16 citations

1976 36 citations

1977 67 citations

1978 94 citations

1979 104 citations

1980 57 citations

1981 122 citations

1982 0 citations

1984 1 citations

1985 55 citations

1986 34 citations

1988 29 citations

1989 3 citations

1990 24 citations

1991 273 citations

1992 4 citations

1993 78 citations

1994 490 citations

1995 310 citations

1996 85 citations

1997 42 citations

1998 1,152 citations

1999 68 citations

2000 78 citations

2001 359 citations

2002 961 citations

2003 131 citations

2004 550 citations

2005 37 citations

2006 771 citations

2008 296 citations

2011 76 citations

2012 167 citations

2016 0 citations

2019 1 citations

M. Peet

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT